Treatment for Insulin Resistance

Phase-Based Progress Estimates
1
Effectiveness
2
Safety
National Institutes of Health Clinical Center, Bethesda, MD
Insulin Resistance+3 More
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial is studying if blocking the effects of growth hormone in the body will help people with severe insulin resistance. This treatment is used to treat Insulin Resistance. All patients in this trial will receive the treatment being studied.

Eligible Conditions

  • Insulin Resistance
  • Insulin Receptor
  • Partial Lipodystrophy

Treatment Effectiveness

Effectiveness Progress

1 of 3

Other trials for Insulin Resistance

Study Objectives

1 Primary · 0 Secondary · Reporting Duration: 1 month

1 month
Glycerol rate of appearance (Ra) normalized to fat mass, Palmitate Ra normalized to fat mass

Trial Safety

Safety Progress

2 of 3
This is further along than 68% of similar trials

Other trials for Insulin Resistance

Trial Design

0 Treatment Group

25 Total Participants · 0 Treatment Group

Primary Treatment: Treatment · No Placebo Group · Phase 2

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 1 month
Closest Location: National Institutes of Health Clinical Center · Bethesda, MD
Photo of maryland 1Photo of maryland 2Photo of maryland 3
2016First Recorded Clinical Trial
6 TrialsResearching Insulin Resistance
277 CompletedClinical Trials

Who is running the clinical trial?

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Lead Sponsor
2,096 Previous Clinical Trials
5,051,861 Total Patients Enrolled
74 Trials studying Insulin Resistance
11,648 Patients Enrolled for Insulin Resistance
Rebecca J Brown, M.D.Principal InvestigatorNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
9 Previous Clinical Trials
1,516 Total Patients Enrolled
3 Trials studying Insulin Resistance
1,218 Patients Enrolled for Insulin Resistance

Eligibility Criteria

Age 18+ · All Participants · 4 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You are female and aged 18-65 years.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.